Tags Archive Navigation
icon
-
Media ReleaseNovartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
-
StoryDrug delivery, service delivery, and the future of cancer care
-
Media ReleaseNovartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
-
StoryInnovation fueled by compassion
-
StoryShoulder to shoulder
-
Media ReleaseNovartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
-
StoryTreatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
-
StoryA scientist from the start – Q&A with NIBR President Fiona Marshall
-
StoryRenewing our commitment to neglected tropical disease and malaria elimination
-
Media ReleaseNovartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
-
Media ReleaseNovartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
-
Media ReleaseNovartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms